Form Type:  8-K
Filing Date:  6/6/2018 
CIK:  0000873303 
Address:  215 FIRST STREET
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-274-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
3.57 (2.65%)  
Trade Time: 
Feb 15  
Market Cap: 
Trade SRPT now with 

© 2019  
Description of Business
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches for the treatment of rare neuromuscular diseases. Applying our proprietary, highly-differentiated and innovative RNA-targeted platform technologies, we are able to develop candidate therapies for a broad range of diseases and disorders. Our first commercial product in the U.S., EXONDYS 51, was granted accelerated approval by the FDA on September 19, 2016. EXONDYS 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. A summary description of our product and main product candidates is as follows: * EXONDYS 51, our first product, uses our PMO chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene.
Register and access this filing in:     
  FORM 8-K
      Item 5.07. Submission of Matters to a Vote of Security Holders.